EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Implanet SA (IMPZY) fair value: what the stock is really worth

We calculate from audited financials what Implanet SA is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jun 23, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ADR · ISIN US45321V1089

IS Implanet SA logo Thin data Jun 23, 2026

Implanet SA

IMPZY · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0170 · Strongly overvalued (−79%)
!Quality 32/100
!Expensive Growth (revenue 5y +26.2 %/yr)
!Loss-making · -35.1% net margin (TTM)
!Moderate debt · negative free cash flow
·0.21% dividend yield
!Trails peers (1/9)
!Narrow moat 6/100
!Evidence only low, so the estimate is less certain
Watch Implanet SA ADR for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.0940 $0.0396 Fair Value $0.0170 Jun 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jun 23, 2026.

How to read this chart

60‑month range $0.0396 – $0.0940 · fair‑value band $0.0085 – $0.0170 · the $0.0800 price screens above the $0.0170 fair value. Dashed = 300-day average. As of Jun 23, 2026.

Follow Implanet SA ADR in your weekly email

Every Wednesday you see whether Implanet SA ADR is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally.

Show more

Implanet S.A., together with its subsidiaries, manufactures and sells implants and medical instruments for orthopedic surgery in France, the United States, Europe, the Middle East, Africa, and internationally. The company offers spinal and knee products, including Jazz PF, Jazz Evo, Jazz Cap SP, Jazz Passer, Jazz Lock, Jazz Claw, Olea, Saxxo, Swingo, Shark, Origin, and Jazz Frame, as well as ISS-Jazz Screw systems for posterior fixation. It also provides an ultrasonic osteotomy surgical system; and knee prostheses under the Madison name. The company exports its products. Implanet S.A. was founded in 2006 and is headquartered in Martillac, France.

Stock analysis

Implanet SA ADR (IMPZY) currently trades at $0.0800, while our model-based Fair Value estimate is $0.0170, implying the stock looks roughly 370.6% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 4 models at a data quality of 95/100, which puts the evidence level at low.

Scenario range: $0.0085 (bear) to $0.0170 (bull), the price of $0.0800 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 32/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

Implanet SA ADR reported revenue of €12.5M in FY2025 versus €6.1M in FY2021, a compound +19.4%/yr. Reported net income was −€4.4M in FY2025.

Key figures

Market cap $233M · P/S ratio 18.4 · Dividend yield 0.2% · Net margin −35.1% · Return on equity −775% · Return on assets (EBIT) −33.6% · Operating margin −31.1% · Revenue (TTM) €12.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 28 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and at its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 5% fair-value upside, at −79%, IMPZY screens richer than that median.

Notify me when IMPZY reaches fair value

Put IMPZY on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 32/100

Of which business quality 33 · Market factors (momentum, volatility) 64

Profitability 23
Margins and returns on capital today
Quality Growth 95
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 39
Balance sheet, leverage, solvency risk
Investment 67
Disciplined investing over empire-building
Low Volatility 95
Calm price path (market factor)
Momentum 40
Price trend over the last 3–12 months (market factor)
52W Momentum 67
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 44/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+32.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+26.2%
Start year 2020 (pandemic). Over 10 years: +6.5% a year
Revenue growth 13 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.0%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−88.0% (2020) → −31.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

IMPZY screens 371% overvalued. Compare with Abbott Laboratories, →

Compare Implanet SA ADR with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 365 stocks

Beats the industry median on 1/9 measures
Overall it trails its industry peers.
Valuation
Quality Score 32 · Bottom 25%
Fair Value upside −79% · Bottom 25%
Profitability
Return on assets −16% · Bottom 25%
Net margin (TTM) −35% · Bottom 25%
Operating margin (TTM) −31% · Bottom 25%
Growth and dividend
Revenue growth 26% · Top 25%
Dividend yield (TTM) 0.2% · Bottom 25%
Balance sheet
Debt / equity 0.61× · Highest 25%

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/S (TTM) 18.66× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 10
FUTURE (revenue growth)100 · sector 31
PAST (return on equity)0 · sector 7
HEALTH (low debt)70 · sector 97
DIVIDEND (yield)0 · sector 40

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Abbott Laboratories, ABT $103.49 $74.79 −28%
Stryker Corporation SYK $273.40 $300.74 +10%
Medtronic plc MDT $89.30 $65.57 −27%
Boston Scientific Corporation BSX $44.62 $49.08 +10%
Edwards Lifesciences Corporation EW $86.82 $82.04 −6%
Siemens Healthineers AG SHL €37.21 €35.22 −5%
DexCom, Inc DXCM $87.73 $96.50 +10%
GE HealthCare Technologies Inc GEHC $66.27 $69.62 +5%
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥156.68 ¥172.35 +10%
Koninklijke Philips N.V PHIA €21.85 €15.32 −30%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Implanet SA ADR · Fair Value
$0.0170 −371%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Implanet SA ADR Fair Value". https://www.fairvalue-calculator.com/stock/IMPZY

Frequently asked questions

Is Implanet SA (IMPZY) overvalued or undervalued?
As of Jun 23, 2026, our model estimates a fair value of $0.0170 versus the last price from Sep 18, 2026 of $0.0800, about −79% upside (overvalued).
What is the fair value of IMPZY?
Our model-based fair value for Implanet SA ADR is $0.0170 (as of Jun 23, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $0.0800.
What is the quality score of IMPZY?
Implanet SA ADR has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Implanet SA (IMPZY)?
Our model-based price target is the fair value of $0.0170 (as of Jun 23, 2026) from 4 valuation models. Cautious scenario $0.0085, optimistic scenario $0.0170. It is a calculation from audited fundamentals, not an analyst target.
What is the Implanet SA ADR stock forecast for 2026?
Our models put fair value at $0.0170, about −79% upside versus the last price from Sep 18, 2026 of $0.0800 (overvalued). Cautious scenario $0.0085, optimistic scenario $0.0170. The calculation is refreshed regularly with new filings.
What is the revenue of Implanet SA (IMPZY)?
Implanet SA ADR reported trailing-twelve-month revenue of about €12.5M (latest available figure, as of Jun 23, 2026).
Does Implanet SA ADR pay a dividend?
Implanet SA ADR currently shows a dividend yield of about 0.21% relative to its recent price (as of Jun 23, 2026).
What is the intrinsic value of Implanet SA (IMPZY)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Implanet SA ADR it is $0.0170 per share (as of Jun 23, 2026), against a price of $0.0800. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is Implanet SA ADR stock overvalued or undervalued in 2026?
As of Jun 23, 2026, IMPZY trades above its calculated fair value: price $0.0800, fair value $0.0170, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of IMPZY?
No. The price is what the market pays today ($0.0800); the fair value is what the company's own numbers justify ($0.0170). For Implanet SA ADR the two are $0.0630 per share apart. That gap is exactly why we show both numbers side by side.
How much is Implanet SA ADR worth?
The market values Implanet SA ADR at about $233M (market capitalisation, as of Jun 23, 2026). Per share that is $0.0800; our models calculate a fair value of $0.0170 per share.
What do the bullish and bearish scenarios say about IMPZY?
Our models span a range for Implanet SA ADR: cautious scenario $0.0085, base $0.0170, optimistic $0.0170 per share (as of Jun 23, 2026, price $0.0800). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Implanet SA (IMPZY)?
Balance-sheet figures for Implanet SA ADR (as of Jun 23, 2026): debt of 0.61 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is IMPZY from its 52-week high?
Implanet SA ADR trades at $0.0800, at its 52-week high of $0.0800 and at the low of $0.0798 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0170 is for.
Which stocks are comparable to Implanet SA ADR?
From the same area (Healthcare) we also value Abbott Laboratories,, Stryker Corporation, Medtronic plc, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Implanet SA ADR stock attractive at the current price?
The data as of Jun 23, 2026: price $0.0800, calculated fair value $0.0170 (−79%), Quality Score 32/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of IMPZY calculated?
We run Implanet SA ADR through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0170, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Implanet SA ADR itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Implanet SA (IMPZY)?
The latest price we hold is from Sep 18, 2026 and stands at $0.0800. Our model-based fair value is $0.0170, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Implanet SA ADR right now?
The price sits above even our optimistic bull case ($0.0170). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.0085 to $0.0170) leaves room in how you read the outcome.

Key figures of Implanet SA ADR

How large is the market capitalisation of Implanet SA (IMPZY)?
The market capitalisation of Implanet SA ADR is $233M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Implanet SA (IMPZY)?
The price-to-sales ratio of Implanet SA ADR is 18.4 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Implanet SA (IMPZY)?
The dividend yield of Implanet SA ADR is 0.2%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Implanet SA (IMPZY)?
The net margin of Implanet SA ADR is −35.1% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Implanet SA (IMPZY)?
The return on equity (ROE) of Implanet SA ADR is −775% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Implanet SA (IMPZY)?
On an EBIT basis the return on assets of Implanet SA ADR is −33.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Implanet SA (IMPZY)?
The operating margin of Implanet SA ADR is −31.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Implanet SA (IMPZY)?
Revenue at Implanet SA ADR is growing +26.0% versus a year earlier (3y avg +15.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Implanet SA (IMPZY) generate?
The free cash flow of Implanet SA ADR is −€2.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Implanet SA (IMPZY) carry?
The net debt of Implanet SA ADR is €2.9M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Implanet SA ADR in the live analysis

One click puts Implanet SA ADR on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.